Angiotensin-converting enzyme activity and angiomodulatory effects of sera in patients with diabetic retinopathy.
Aberrant neovascularization plays a crucial role in ocular complications in diabetic patients. Sera from these patients contain high levels of angiostimulatory factors, the most important of which is vascular endothelial growth factor (VEGF). Many authors have described elevation of angiotensin-converting enzyme (ACE) activity in the sera of diabetic patients. It is important to determine the possible relationship between these two phenomena. We studied ACE serum activity and VEGF concentrations in patients with type 1 and type 2 diabetes and retinopathy We also investigated the effect of their sera on cutaneous angiogenesis induced in mice by grafting healthy human mononuclear blood leukocytes. We found a negative correlation between the angiostimulatory effect and ACE level in the sera of patients with type 1 diabetes and no correlation between these two parameters in patients with type 2 diabetes. VEGF concentrations were lower and ACE activity was significantly higher in the sera of patients with type 1 diabetes than in the sera of those with type 2 diabetes.
Skopiński
P
P
Department of Electron Microscopy, Institute of Biostructure, Warsaw Medical Academy, Poland.
Sommer
E
E
Borowska
A
A
Hevelke
A
A
Rogala
E
E
Skopińska-Rózewska
E
E
D000328:Adult; D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000201:enzymology / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000201:enzymology / Q000473:pathology; D003930:Diabetic Retinopathy / Q000097:blood* / Q000201:enzymology* / Q000473:pathology; D016228:Endothelial Growth Factors / Q000097:blood; D005260:Female; D006801:Humans; D008222:Lymphokines / Q000097:blood; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009000:Monocytes / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000139:chemically induced*; D007703:Peptidyl-Dipeptidase A / Q000097:blood*; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D007703:Peptidyl-Dipeptidase A